000162952 001__ 162952
000162952 005__ 20251017144637.0
000162952 0247_ $$2doi$$a10.1002/adma.202510355
000162952 0248_ $$2sideral$$a145438
000162952 037__ $$aART-2025-145438
000162952 041__ $$aeng
000162952 100__ $$0(orcid)0000-0003-1599-8216$$aLanda, Guillermo$$uUniversidad de Zaragoza
000162952 245__ $$aBacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
000162952 260__ $$c2025
000162952 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162952 5203_ $$aBacteria exhibit adaptive phenotypic traits that confer resistance to host defenses and antimicrobial therapies. In response to the global threat of antimicrobial resistance, bacteria‐responsive nanostructured drug delivery systems have emerged as a promising alternative to conventional broad‐spectrum antimicrobials. These systems release therapeutics selectively in response to bacterial presence or to their secreted enzymes, toxins, antigens, or extracellular biomarkers, enabling precise activation at infection sites while minimizing off‐target effects. Bacterial components such as membrane proteins, signaling molecules, biofilm‐associated glycolipids, and enzymes (e.g., lipase, hyaluronidase) serve as triggers for these smart carriers. Exopolysaccharides are also commonly targeted using nanocarriers with complementary recognition elements. Such systems are often surface‐modified or loaded with antimicrobials for on‐demand release. Benefits include enhanced selectivity, reduced side effects, improved biofilm penetration, higher intracellular accumulation, and potential for personalized therapy. A variety of materials—including lipid‐based carriers, metal nanoparticles, polymer nanoparticles, and inorganic nanomaterials—have been engineered to release antimicrobials only in the presence of pathogenic bacteria, often offering dual therapeutic effects (e.g., anti‐inflammatory). Furthermore, many platforms integrate multiple antimicrobial mechanisms, reducing the likelihood of resistance development. This review highlights recent preclinical studies validating bacteria‐responsive nanosystems and underscores their advantages over passive drug delivery and conventional free antimicrobials.
000162952 536__ $$9info:eu-repo/grantAgreement/ES/DGA/PROY_B21_24$$9info:eu-repo/grantAgreement/ES/ISCIII/FORT23-00028$$9info:eu-repo/grantAgreement/ES/ISCIII/MS19-00092$$9info:eu-repo/grantAgreement/ES/MICINN/PID2023-146091OB-I00$$9info:eu-repo/grantAgreement/ES/MICIU/CEX2023-001286-S
000162952 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000162952 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162952 700__ $$0(orcid)0000-0003-2293-363X$$aMendoza, Gracia
000162952 700__ $$0(orcid)0000-0002-2966-9088$$aIrusta, Silvia
000162952 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, Manuel$$uUniversidad de Zaragoza
000162952 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000162952 773__ $$g(2025), e10355 [31 pp.]$$pAdv. mater.$$tAdvanced materials$$x0935-9648
000162952 8564_ $$s12899835$$uhttps://zaguan.unizar.es/record/162952/files/texto_completo.pdf$$yVersión publicada
000162952 8564_ $$s2734287$$uhttps://zaguan.unizar.es/record/162952/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162952 909CO $$ooai:zaguan.unizar.es:162952$$particulos$$pdriver
000162952 951__ $$a2025-10-17-14:30:06
000162952 980__ $$aARTICLE